In Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus
In Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus
复制标题
DOI：
10.3390/pathogens9010067
复制
发表时间：
2020-01-01
期刊：
影响因子：
3.7
通讯作者：
Takano, Tomomi
中科院分区：
文献类型：
--
作者：
Doki, Tomoyoshi;Tarusawa, Tomoyo;Takano, Tomomi
背景：阳离子两亲性药物U18666A在体外可抑制I型FIPV的增殖。在本研究中，我们通过将U18666A应用于感染I型FIPV的SPF猫，评估了U18666A的体内抗病毒作用。方法：将10只SPF级猫随机分为两组。将FIPVKU-2接种于猫的腹腔内。对照组给予PBS，U18666A治疗组于接种病毒后第0d皮下注射U18666A 2.5 mg/kg，第2、4d皮下注射U18666A 1.25 mg/kg。结果：5只单独服用PBS的对照猫中有2只发生FIP。接受U18666A治疗的五只猫中有四只没有出现FIP的迹象。一只猫暂时发烧，没有其他临床症状，在实验结束后的尸检中没有发现肉眼病变。在粪便和唾液中间歇性地检测到FIPV基因，无论FIP的发展或U18666A的给药。结论：实验感染I型FIPV的猫给予U18666A治疗，与对照组相比，可抑制FIP的发展。然而，感染FIP的动物数量太少，不能证实U18666A对猫的抗病毒作用。
Background: The cationic amphiphilic drug U18666A inhibits the proliferation of type I FIPV in vitro. In this study, we evaluated the in vivo antiviral effects of U18666A by administering it to SPF cats challenged with type I FIPV. Methods: Ten SPF cats were randomly assigned to two experimental groups. FIPV KU-2 were inoculated intraperitoneally to cats. The control group was administered PBS, and the U18666A-treated group was administered U18666A subcutaneously at 2.5 mg/kg on day 0, and 1.25 mg/kg on days 2 and 4 after viral inoculation. Results: Two of the five control cats administered PBS alone developed FIP. Four of the five cats administered U18666A developed no signs of FIP. One cat that temporarily developed fever, had no other clinical symptoms, and no gross lesion was noted on an autopsy after the end of the experiment. The FIPV gene was detected intermittently in feces and saliva regardless of the development of FIP or administration of U18666A. Conclusions: When U18666A was administered to cats experimentally infected with type I FIPV, the development of FIP might be suppressed compared with the control group. However, the number of animals with FIP is too low to establish anti-viral effect of U18666A in cats.